Royal Philips has expanded its home care portfolio for chronic obstructive pulmonary disease (COPD) patients with the launch of a non-invasive Philips Ventilator BiPAP A40 EFL.
The latest device helps pulmonologists to identify COPD patients with expiratory flow limitation (EFL) and treat them with targeted therapy to reduce symptoms and provide better comfort during sleep.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Over 50% of COPD patients experience EFL, which is defined as limited exhalation of breath from the lungs.
Depending on the patient’s needs, the BiPAP A40 EFL ventilator can continuously adjust pressure.
The first-of-its-kind device helps healthcare professionals to automatically screen, detect, and abolish EFL to reduce the burden while breathing in COPD patients with abnormally elevated blood carbon dioxide levels.
Philips respiratory care business leader Eli Diacopoulos said: “EFL often goes undetected, meaning patients don’t receive the care they need to improve their disease.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“BiPAP A40 EFL aims to revolutionise COPD care solutions. Clinicians can now detect EFL in hypercapnic COPD patients at the point of care, ensure personalised patient treatment at home and monitor care remotely.”
BiPAP A40 EFL has been built with Philips ExpiraFlow technology and can connect from diagnostic work to point-of-care therapy.
The device can also streamline diagnostic work through integration to its Alice sleep lab and home diagnostic systems by using Philips’ connected solution platform.
In the at-home setting, the BiPAP A40 EFL connects to Philips Care Orchestrator cloud-based care management system.
It will enable healthcare providers to make quick and more informed decisions and identify and prioritise patients who require therapeutic intervention.
Initially, the CE marked device BiPAP A40 EFL will be available for sale in selected countries in Europe and expansion to additional European markets is anticipated next year.
